Introduction Cholecystitis is a highly prevalent disease that imposes a substantial burden on the healthcare system. Despite strong underlying evidence, guideline adherence in the treatment of ...

The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC). "The extended VANTAGE analysis provides encouraging insights into the ...

Top-line results from the Phase III GLISTEN trial (NCT04950127) show that the novel therapy linerixibat produced a significant reduction in pruritus in adult patients with primary biliary cholangitis ...

We report a middle-aged lady who developed a rectal stricture on the background of ulcerative colitis and primary sclerosing cholangitis. Although initial endoscopic biopsies showed no dysplasia, the ...

Investigators enrolled 238 people with the liver disease primary biliary cholangitis and cholestatic pruritus, a medical term for relentless itch. After 24 weeks of oral dosing, scores on a 10 ...

1 1. Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with ...

Image credit: Shutterstock / mi_viri Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing cholangitis (PSC). In the pivotal, Phase III ...

There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.

for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to ...

There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk ...